Karen S. McColl

Karen S. McColl

Auto-generated profile, based on publicly available information

Karen S. McColl

Division of Hematology and Oncology, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
GWGary Wildey
Gary Wildey
ASAshley M. Shay
Ashley M. Shay
KMKaren S. McColl
Karen S. McColl
SYSuzy Yoon
Suzy Yoon
MSMohammad A. Shatat
Mohammad A. Shatat
ADAfshin Dowlati
Afshin Dowlati
The canonical model of “small cell lung cancer” (SCLC) depicts tumors arising from dual inactivation of TP53 and RB1. However, many genomic studies have persistently identified tumors with no RB1 mutations. Here, we examined RB1 protein expression and function in SCLC. RB1 expression was examined by IHC analysis of 62 human SCLC tumors. These studies showed that ∼14% of SCLC tumors expressed abundant RB1 protein, which is associated with neuroendocrine gene expression and is enriched in YAP1 expression, but no other lineage proteins that stratify SCLC. SCLC cells and xenograft tumors with RB1 protein expression were sensitive to growth inhibition by the CDK4/6 inhibitor palbociclib, and this inhibition was shown to be dependent on RB1 expression by CRISPR knockout. Furthermore, a patient with biopsy-validated wild-type RB1 SCLC who received the CDK4/6 inhibitor abemaciclib demonstrated a dramatic decrease in mutant TP53 ctDNA allelic fraction from 62.1% to 0.4% and decreased tumor mass on CT scans. Importantly, IHC of the diagnostic biopsy specimen showed RB1 positivity. Finally, we identified a transcriptomics-based RB1 loss-of-function signature that discriminates between SCLC cells with or without RB1 protein expression and validated it in the patient who was responsive to abemaciclib, suggesting its potential use to predict CDK4/6 inhibitor response in patients with SCLC. Our study demonstrates that RB1 protein is an actionable target in a subgroup of SCLC, a cancer that exhibits no currently targetable mutations.

20 October 2020 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
THTian He
Tian He
GWGary Wildey
Gary Wildey
KMKaren McColl
Karen McColl
ASAlyssa Savadelis
Alyssa Savadelis
KSKyle Spainhower
Kyle Spainhower
ADAfshin Dowlati
Afshin Dowlati
Small‐cell lung cancer (SCLC) can be subgrouped into common ‘pure’ and rare ‘combined’ SCLC (c‐SCLC). c‐SCLC features a mixed tumor histology of both SCLC and non–small‐cell lung cancer (NSCLC). We performed targeted exome sequencing on 90 patients with SCLC, including two with c‐SCLC, and discovered RUNX1T1 amplification specific to small cell tumors of both patients with c‐SCLC, but in only 2 of 88 ‘pure’ SCLC patients. RUNX1T1 was first identified in the fusion transcript AML1/ETO, which occurs in 12%‐15% of acute myelogenous leukemia (AML). We further show higher expression of RUNX1T1 in the SCLC component of another c‐SCLC tumor by in situ hybridization. RUNX1T1 expression was enriched in SCLC compared with all other cancers, including NSCLC, in both cell lines and tumor specimens, as shown by mRNA level and western blotting. Transcriptomic analysis of hallmark genes decreased by stable RUNX1T1 overexpression revealed a significant change in E2F targets. Validation experiments in multiple lung cancer cell lines showed that RUNX1T1 overexpression consistently decreased CDKN1A (p21) expression and increased E2F transcriptional activity, which is commonly altered in SCLC. Chromatin immunoprecipitation (ChIP) in these overexpressing cells demonstrated that RUNX1T1 interacts with the CDKN1A (p21) promoter region, which displayed parallel reductions in histone 3 acetylation. Furthermore, reduced p21 expression could be dramatically restored by HDAC inhibition using Trichostatin A. Reanalysis of ChIP‐seq data in Kasumi‐1 AML cells showed that knockdown of the RUNX1T1 fusion protein was associated with increased global acetylation, including the CDKN1A (p21) promoter. Thus, our study identifies RUNX1T1 as a biomarker and potential epigenetic regulator of SCLC.

20 November 2009 in Blood
Verified
Journal Article
Open access
MHMichael W Harr
Michael W Harr
PCpaolo caimi
paolo caimi
KMKaren McColl
Karen McColl
FZFei Zhong
Fei Zhong
SPShilen N Patel
Shilen N Patel
CDClark W. Distelhorst
Clark W. Distelhorst
Abstract 4811 Glucocorticoid hormones are frequently used as part of front-line therapy to treat lymphoid neoplasms. However, relative to acute lymphoblastic leukemia and many types of B cell lymphoma, chronic lymphocytic leukemia (CLL) cells are intrinsically resistant to glucocorticoids and the mechanism governing this resistance has not been fully investigated. Here we report that that the Src inhibitor dasatinib enhances glucocorticoid-induced apoptosis in lymphoid cells and sensitizes primary CLL cells to dexamethasone. This finding evolved from the observation that the Src kinase Lck was downregulated by dexamethasone in glucocorticoid sensitive T cells in order to suppress immunoreceptor activation and signaling. In contrast, aberrantly expressed Lck was not downregulated by dexamethasone in CLL cells. However, inhibition of Lck phosphorylation by dasatinib significantly enhanced cell killing to nanomolar concentrations of dexamethasone. Collectively, these data indicate that dasatinib sensitizes primary CLL cells to glucocorticoids, and thus, the combination of these agents may have therapeutic efficacy in patients with aggressive or refractory CLL.

1 November 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JMJason K. Molitoris
Jason K. Molitoris
KMKaren S. McColl
Karen S. McColl
SSSarah Swerdlow
Sarah Swerdlow
MMMieko Matsuyama
Mieko Matsuyama
MLMinh Lam
Minh Lam
CDClark W. Distelhorst
Clark W. Distelhorst

21 October 2008 in BMJ
Verified
Journal Article
Closed access
KMKaren McColl
Karen McColl
Mary Robinson, co-chair of WHO’s working group on health worker migration policy, tells Karen McColl about a proposed global code of practice on international recruitment of health workers